Prodotti della ricerca
UNICA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Cagliari dal mese di luglio 2015.
| Titolo | Data di pubblicazione | Autore(i) | Rivista | Editore |
|---|---|---|---|---|
| Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age | 2019 | Costa, Giulia; Porceddu, Pier Francesca; Serra, Marcello; Casu, Maria Antonietta; Schiano, Valent...ina; Napolitano, Francesco; Pinna, Annalisa; Usiello, Alessandro; Morelli, Micaela | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | |
| Fos expression induced by olanzapine and risperidone in the central extended amygdala | 2019 | Pinna, A.; Costa, G.; Contu, L.; Morelli, M. | EUROPEAN JOURNAL OF PHARMACOLOGY | |
| Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia | 2018 | Pinna, Annalisa; Serra, Marcello; Morelli, Micaela; Simola, Nicola | JOURNAL OF NEURAL TRANSMISSION | |
| Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway | 2018 | Renaud, Justine; Bassareo, Valentina; Beaulieu, Jimmy; Pinna, Annalisa; Schlich, Michele; Lavoie,... Carole; Murtas, Daniela; Simola, Nicola; Martinoli, Maria-Grazia | NEUROBIOLOGY OF AGING | |
| Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease | 2016 | Baranyi, M; Porceddu, Pf; Goloncser, F; Kulcsar, S; Otrokocsi, L; Kittel, A; Pinna, A; Frau, L; H...uleatt, Pb.; Khoo, Ml; Chai, Cll.; Dunkel, P; Matyus, P; Morelli, M; Sperlagh, B | MOLECULAR NEURODEGENERATION | |
| The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging | 2016 | Pinna, A; Napolitano, F; Pelosi, B; Di Maio, A; Wardas, J; Casu, Ma; Costa, G; Migliarini, S; Cal...abresi, P; Pasqualetti, M; Morelli, M; Usiello, A | MOVEMENT DISORDERS | |
| Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease | 2016 | Pinna, A; Ko, WKD; Costa, G; Tronci, E; Fidalgo, C; Simola, N; Li, Q; Tabrizi, MA; Bezard, E; Car...ta, M; Morelli, M | MOVEMENT DISORDERS | |
| Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease | 2015 | Fuzzati-Armentero, MT; Cerri, S; Levandis, G; Ambrosi, G; Montepeloso, E; Antoninetti, G; Blandin...i, F; Baqi, Y; Muller, CE; Volpini, R; Costa, G; Simola, N; Pinna, A | JOURNAL OF NEUROCHEMISTRY | |
| Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists | 2014 | SIMOLA N; PINNA A; FRAU L; MORELLI M | Springer | |
| A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists | 2014 | PINNA A; MORELLI M | NEUROTOXICITY RESEARCH | |
| L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies | 2014 | PINNA A; BONAVENTURA J; FARRE D; SANCHEZ M; SIMOLA N; MALLOL J; LLUIS C; COSTA G; BAQI Y; MULLER ...CE; CORTES A; McCORMICK P; CANELA EI; MARTINEZ-PINILLA E; LANCIEGO JL; CASADO' V; ARMENTERO MT; FRANCO R | EXPERIMENTAL NEUROLOGY | |
| Antiparkinsonian actions and interactions of adenosine antagonists | 2014 | Morelli, M.; Costa, G.; Pinna, A. | PURINERGIC SIGNALLING | |
| Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease | 2013 | PINNA A; SIMOLA N; FRAU L; MORELLI M | Springer Science | |
| Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward | 2012 | SIMOLA N; FENU S; COSTA G; PINNA A; PLUMITALLO A; MORELLI M | NEUROPHARMACOLOGY | |
| Late-onset Parkinsonism in NFκB/c-Rel-deficient mice | 2012 | Baiguera, C; Alghisi, M; Pinna, A; Bellucci, A; DE LUCA, Ma; Frau, L; Morelli, M; Ingrassia, R; B...enarese, M; Porrini, V; Pellitteri, M; Bertini, G; Fabene, Pf; Sigala, S; Spillantini, Mg; Liou, Hc; Spano, Pf; Pizzi, M | BRAIN | |
| Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration | 2011 | SGADO' P; VIAGGI C; PINNA A; MARRONE C; VAGLINI F; PONTIS S; MERCURI NB; MORELLI M; CORSINI GU | NEUROTOXICITY RESEARCH | |
| Pharmacological therapy of Parkinson's disease: current options and new avenues | 2010 | Simola, N; Pinna, A; Fenu, S | RECENT PATENTS ON CNS DRUG DISCOVERY | |
| Farmaci antiparkinsoniani ed attivi in altri disturbi motori | 2010 | Carta, Annarosa; Pinna, Annalisa; Corsini, Giovanni Umberto; Caramelli, Andrea; Morelli, Micaela | Idelson-Gnocchi | |
| A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug | 2010 | Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M | NEUROPHARMACOLOGY | |
| Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease | 2009 | Kasture, S; Pontis, S; Pinna A; Schintu, N; Spina, L; Longoni, R; Simola, N; Ballero, M; Morelli, M | NEUROTOXICITY RESEARCH |
